Month: November 2011

Mergers & Acquisitions

Anglo American Agree 40% Acquisition in De Beers – Video Interview

November 4, 2011 0

Anglo American Agree 40% Acquisition in De Beers – Video Interview PR Newswire LONDON, November 4, 2011 LONDON , November 4, 2011 /PRNewswire/ — In a video interview with financial broadcaster http://www.cantos.com , Anglo American Chief Executive Cynthia Carroll discusses the acquisition of the Oppenheimer family’s 40% interest in De Beers for US$5.1 billion . She explains why now is the time to go forward with the acquisition and why the deal marks Anglo American’s commitment to a “highly attractive industry”. […]

Momentum Stocks

Delta Air Lines (DAL) – Bull of the Day (DAL)

November 4, 2011 0

We are upgrading our recommendation on Delta Air Lines ( DAL ) to Outperform based on third quarter results, which matched the Zacks Consensus Estimate, and continuous cost reduction initiatives. Despite soaring fuel prices, earnings on a GAAP basis climbed on fare hikes, capacity cuts and unbundled offerings. […]

Mad Money Episodes

Wheat from Chaff

November 3, 2011 0

[cnbc 3000055205] Mad Money host Jim Cramer says we’re witnessing companies facing identical sets of circumstances during this earnings season. And while some are hitting it out of the park, others are whiffing. […]

Mergers & Acquisitions

XTL Biopharmaceuticals to Acquire NiCure

November 3, 2011 0

XTL Biopharmaceuticals to Acquire NiCure NiCure for the treatment of cartilage-related diseases, focusing on the treatment of Osteoarthritis; A technology of Mor Research Applications, the TTO of Clalit Health Services, Israel’s largest HMO with approximately 4 million members PR Newswire HERZELIYA, Israel, November 3, 2011 HERZELIYA, Israel , November 3, 2011 /PRNewswire/ — On November 2, 2011 , XTL Biopharmaceuticals, Ltd. (the “Company”) announced that it entered into a term sheet by which it will acquire a technology (“NiCure”) from Mor Research Applications, the Technology Transfer Office (TTO) of Clalit Health Services, by obtaining an exclusive license to use the entire technology and intellectual property in return for royalties on sales and milestone payments throughout the clinical development process. The agreement that will be signed by the parties is subject to, among others, the completion of due diligence, examination of the regulatory environment for the continued development of the drug, and the approval of the Company’s board […]